{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:06:25Z","timestamp":1766268385763,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM007863"],"award-info":[{"award-number":["GM007863"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1-AI110557-05","UM1-AI144298-01"],"award-info":[{"award-number":["UM1-AI110557-05","UM1-AI144298-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple sclerosis (MS) is a progressive autoimmune demyelinating disorder. Recent studies suggest that a combination of genetic susceptibility and environmental insult contributes to its pathogenesis. Many candidate genes have been discovered to modulate susceptibility for developing MS by genome wide association studies (GWAS); these include major histocompatibility complex (MHC) genes and non-MHC genes. MS cases in the context of genetic diseases may provide different approaches and clues towards identifying novel genes and pathways involved in MS pathogenesis. Here, we present a case series of two related patients with concomitant Von Hippel-Lindau disease (VHLD) and MS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We present two patients, a mother (case 1) and daughter (case 2), who developed superimposed relapsing-remitting multiple sclerosis in the background of the autosomal dominant genetic disorder VHLD. Several tumors characteristic of VHLD developed in both cases with pancreatic and renal neoplasms and cerebellar hemangioblastomas. In addition, both patients developed clinical symptoms consistent with multiple sclerosis, supported by radiologic lesions disseminating in time and space.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Though non-MHC susceptibility genes remain elusive in MS, we present the striking finding of superimposed multiple sclerosis in a mother and daughter with VHLD. The VHL gene is known to be the primary regulator of Nrf2, the well-established target of the FDA-approved therapeutic dimethyl fumarate. These cases provide support for further studies to determine whether VHLD pathway related genes represent a novel genetic link in multiple sclerosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02604-6","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T08:02:38Z","timestamp":1646726558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Familial multiple sclerosis in patients with Von Hippel-Lindau disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Samir R.","family":"Nath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhjot","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Mao-Draayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"issue":"12","key":"2604_CR1","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1097\/IAE.0000000000002555","volume":"39","author":"ME Aronow","year":"2019","unstructured":"Aronow ME, et al. VON HIPPEL-LINDAU DISEASE: update on pathogenesis and systemic aspects. Retina. 2019;39(12):2243\u201353.","journal-title":"Retina"},{"key":"2604_CR2","doi-asserted-by":"publisher","first-page":"5669","DOI":"10.2147\/OTT.S190753","volume":"13","author":"S Glasker","year":"2020","unstructured":"Glasker S, et al. Von Hippel-Lindau disease: current challenges and future prospects. Onco Targets Ther. 2020;13:5669\u201390.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"2604_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/jmg.28.7.443","volume":"28","author":"ER Maher","year":"1991","unstructured":"Maher ER, et al. Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991;28(7):443\u20137.","journal-title":"J Med Genet"},{"issue":"8761","key":"2604_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/0140-6736(91)90401-A","volume":"338","author":"HP Neumann","year":"1991","unstructured":"Neumann HP, Wiestler OD. Clustering of features and genetics of von Hippel-Lindau syndrome. Lancet. 1991;338(8761):258.","journal-title":"Lancet"},{"key":"2604_CR5","unstructured":"van Leeuwaarde RS,\u00a0Ahmad S,\u00a0Links TP,\u00a0et al. Von Hippel-Lindau Syndrome.\u00a02000 May 17 [Updated 2018 Sep 6].\u00a0In: Adam MP, Ardinger HH, Pagon RA, et al., editor.\u00a0GeneReviews\u00ae\u00a0[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022."},{"issue":"11","key":"2604_CR6","doi-asserted-by":"publisher","first-page":"e3801","DOI":"10.1371\/journal.pone.0003801","volume":"3","author":"KE Hacker","year":"2008","unstructured":"Hacker KE, Lee CM, Rathmell WK. VHL type 2B mutations retain VBC complex form and function. PLoS One. 2008;3(11):e3801.","journal-title":"PLoS One"},{"issue":"5","key":"2604_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","volume":"169","author":"GA Collins","year":"2017","unstructured":"Collins GA, Goldberg AL. The logic of the 26S proteasome. Cell. 2017;169(5):792\u2013806.","journal-title":"Cell"},{"issue":"5516","key":"2604_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1126\/science.1059817","volume":"292","author":"M Ivan","year":"2001","unstructured":"Ivan M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464\u20138.","journal-title":"Science"},{"issue":"1","key":"2604_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","volume":"12","author":"B Keith","year":"2011","unstructured":"Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011;12(1):9\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2604_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1352458517737371","volume":"24","author":"E Canto","year":"2018","unstructured":"Canto E, Oksenberg JR. Multiple sclerosis genetics. Mult Scler. 2018;24(1):75\u20139.","journal-title":"Mult Scler"},{"issue":"14","key":"2604_CR11","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1093\/hmg\/ddi206","volume":"14","author":"DA Dyment","year":"2005","unstructured":"Dyment DA, et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet. 2005;14(14):2019\u201326.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2604_CR12","doi-asserted-by":"publisher","first-page":"e29819","DOI":"10.1371\/journal.pone.0029819","volume":"7","author":"A Alcina","year":"2012","unstructured":"Alcina A, et al. Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations. PLoS One. 2012;7(1):e29819.","journal-title":"PLoS One"},{"issue":"8","key":"2604_CR13","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.4049\/jimmunol.181.8.5473","volume":"181","author":"SJ Caillier","year":"2008","unstructured":"Caillier SJ, et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol. 2008;181(8):5473\u201380.","journal-title":"J Immunol"},{"issue":"1\u20132","key":"2604_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneuroim.2005.04.027","volume":"167","author":"E Prat","year":"2005","unstructured":"Prat E, et al. HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype. J Neuroimmunol. 2005;167(1\u20132):108\u201319.","journal-title":"J Neuroimmunol"},{"issue":"6460","key":"2604_CR15","doi-asserted-by":"publisher","first-page":"eaav7188","DOI":"10.1126\/science.aav7188","volume":"365","author":"International Multiple Sclerosis Genetics, Consortium","year":"2019","unstructured":"International Multiple Sclerosis Genetics, Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460):eaav7188.","journal-title":"Science"},{"issue":"17\u201318","key":"2604_CR16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1101\/gad.338046.120","volume":"34","author":"X Ding","year":"2020","unstructured":"Ding X, et al. The Daam2-VHL-Nedd4 axis governs developmental and regenerative oligodendrocyte differentiation. Genes Dev. 2020;34(17\u201318):1177\u201389.","journal-title":"Genes Dev"},{"issue":"6","key":"2604_CR17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","volume":"47","author":"C Lucchinetti","year":"2000","unstructured":"Lucchinetti C, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707\u201317.","journal-title":"Ann Neurol"},{"issue":"7796","key":"2604_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-020-1999-0","volume":"578","author":"MA Wheeler","year":"2020","unstructured":"Wheeler MA, et al. MAFG-driven astrocytes promote CNS inflammation. Nature. 2020;578(7796):593\u20139.","journal-title":"Nature"},{"issue":"4","key":"2604_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.2174\/157015912804499519","volume":"10","author":"JW Thompson","year":"2012","unstructured":"Thompson JW, Narayanan SV, Perez-Pinzon MA. Redox signaling pathways involved in neuronal ischemic preconditioning. Curr Neuropharmacol. 2012;10(4):354\u201369.","journal-title":"Curr Neuropharmacol"},{"issue":"6","key":"2604_CR20","doi-asserted-by":"publisher","first-page":"13885","DOI":"10.3390\/ijms160613885","volume":"16","author":"Q Wang","year":"2015","unstructured":"Wang Q, et al. Dimethyl fumarate protects neural stem\/progenitor cells and neurons from oxidative damage through Nrf2-ERK1\/2 MAPK pathway. Int J Mol Sci. 2015;16(6):13885\u2013907.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02604-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02604-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02604-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T08:02:58Z","timestamp":1646726578000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02604-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2604"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02604-6","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2022,3,8]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval is not applicable. All patients provided informed consents prior to submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consents were obtained from the patients for publication of this case report and any accompanying images. Consents for minors were obtained from a parent. Copies of the written consents are available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SRN, PG, and TC have nothing to disclose. YMD has served as a consultant and\/or received grant support from: Acorda, Bayer Pharmaceutical, Biogen Idec, Celgene\/Bristol Myers Squibb, EMD Serono, Sanofi-Genzyme, Roche-Genentech, Novartis, Questor, Janssen, and Teva Neuroscience.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}